Compare iShares International Treasury Bond ETF (IGOV) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares International Treasury Bond ETF trades at $41.13, while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: iShares International Treasury Bond ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| IGOV | RXRX | |
|---|---|---|
52-Week High | $43.09 | $6.79 |
52-Week Low | $40.35 | $2.84 |
Market Cap | — | $1.81B |
Sector | — | Health |
Enterprise Value | — | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
